Response of prostate cancer to addition of dutasteride after progression on abiraterone

Asian J Androl. 2021 Mar-Apr;23(2):222-223. doi: 10.4103/aja.aja_45_20.

Authors

Jian-Po Lian¹, Yuan-Yuan Gao², Jing-Jie Tang², Xi Chen¹, Ying Liu¹, Deng-Long Wu¹, Zhen-Fei Li², Sheng-Song Huang¹

Affiliations

¹ Department of Urology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
² State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai 200031, China.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Androstenes / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Disease Progression
Drug Resistance, Neoplasm
Dutasteride / administration & dosage
Humans
Male
Prednisone / administration & dosage
Progression-Free Survival
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology

Substances

Androstenes
abiraterone
Dutasteride
Prednisone